CAMBRIDGE, Mass., July 07, 2025 - Generation Bio Co. (Nasdaq: GBIO), a biotechnology company focused on T cell-driven autoimmune diseases, announced the granting of equity awards to a new employee under its 2025 Inducement Stock Incentive Plan. This grant, issued on July 1, 2025, includes non-statutory stock options to purchase 128,600 shares of the company's common stock at an exercise price of $0.32 per share, matching the closing price on the grant date. The stock options have a 10-year term, with a vesting schedule of 25% on the first anniversary of the employee's start date, and 6.25% vesting quarterly thereafter, contingent on continued employment with the company. The inducement grant adheres to the award agreements and the 2025 Inducement Stock Incentive Plan terms.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.